Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

Fig. 1

Adjusted mean least squares (LS) change from baseline in a fatigue, b sleep disturbance, c pain, and d Health Assessment Questionnaire-Disability Index (HAQ-DI) (intention-to-treat population, last observation carried forward; placebo n = 212, CZP n = 851). a p < 0.001 for CZP vs. placebo by analysis of covariance (ANCOVA); b p ≤ 0.01 for CZP vs. placebo by ANCOVA. CZP certolizumab pegol; FAS Fatigue Assessment Scale, MOS-SPI Sleep Problem Index II domain of the 12-item Medical Outcomes Study Sleep Scale, OLE open-label extension, VAS visual analogue scale

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us